CClinicalTrials.gg
Status unknownNCT01922869COBUpdated Aug 14, 2013

An Acute Human Intervention With Flavonoid to Investigate Absorption, Metabolism and Excretion

An interventional study of Flavonoids in Pharmacokinetics of Flavonoids in Humans, sponsored by University of East Anglia. Status unknown at 1 site in United Kingdom. Open to participants aged 18 Years to 77 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2013-08-14.

Sponsored by University of East Anglia · Not applicable, Interventional, and Basic science

The sponsor has not verified this record recently (last verified Aug 2013), so the status shown — last known as Recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
240
Allocation
Not applicable
Ages
18 Years to 77 Years
Sex
All
01

Study summary

The era of general dietary recommendations for the whole population may be coming to an end, as it is becoming apparent that we are all unique and do not respond in the same way to the same foods. Within a decade it is believed that doctors will be able to take profiles of their patients, identify specific diseases for which they are at risk and create personalised nutrition plans accordingly. At the University of East Anglia, UK the investigators are interested in particular food compounds known as flavonoids which can be found in foods such as chocolate, orange juice and blackberries (COB). The study will determine if factors such as age, gender, genetics and the bacteria present in our guts contribute to variability between individuals in their absorption, metabolism and excretion of flavonoids.

Read the detailed description

The study will recruit men and women who are aged either 18-30 or 65-77 years and are generally healthy.On arriving at the study day we will collect a blood sample. Breakfast will then be supplied in the form of a food or drink that will contain freezedried powder from orange juice, chocolate and blackberry. After breakfast further blood samples will be taken at several time points throughout the day. Urine and faeces samples will also be collected. These biological samples will be tested for flavonoid absorption, metabolism and excretion as well as influence of genetic make-up of individuals and the gut microflora harboured in faecal samples.

02

Conditions studied

  • Pharmacokinetics of Flavonoids in Humans

Keywords

  • Absorption
  • Metabolism
  • Excretion
  • Flavonoids
  • Polyphenols
  • Genes
  • Gut-microflora
03

In context

Lead sponsor

University of East Anglia is the lead sponsor of 73 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 77 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Male or Female
  • Caucasian of European origin
  • Age either between 18-30 years or between 65-77 years

Exclusion criteria

Exclusion Criteria:

  • BMI \< 18.5 kg/m2 or BMI > 30 kg/m2
  • Smokers or nicotine users
  • High (above 140/90 mmHg ) or low (less than 90/60 mmHg) blood pressure
  • Having any existing medical conditions or significant past medical history likely to affect study measurements e.g., type 2 diabetes, cardiovascular, renal, liver or gastrointestinal diseases
  • Unsatisfactory biochemical, haematological or urinary assessment, indicating abnormal; renal or liver function, full blood profile, impaired glucose handling, deranged lipids or measurements considered to be counter indicative of the study by the clinical advisor
  • Taking any prescribed medication that could interact with the enzymes involved in the metabolism of flavonoids
  • Taking flavonoid containing supplements or other dietary supplements for one month prior to the study (and duration of the study intervention)
  • Known allergies to the intervention foods
  • Consume more alcoholic beverages on average than 21 units/wk for men, or 14 units/wk for women (The UK Department of Health recommendations)
  • Pregnant, breast feeding, or planning a pregnancy (or having fertility treatment)
  • Unable to provide informed consent to participate in the study
05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
240 participants (estimated)

Study arms

  • Experimental
    COB mixture

    One time ingestion of flavonoid mixture from chocolate (80 g), orange juice (500 ml)and blackberries (160 g), also known as the 'COB mixture' providing approximately 640 mg of flavan-3-ols, 390 mg of anthocyanins and 342 mg of flavanones respectively.

    Dietary Supplement: Flavonoids

Interventions

  • Dietary supplementFlavonoids
06

What researchers measure

Primary outcomes

  1. Flavanoid metabolites

    Concentrations of flavonoid metabolites will be assessed using state-of-the-art liquid chromatography-tandem mass spectrometry (LC-MS/MS) and quantified against commercially available standards. Serum and urine will be acidified and then extracted by solid phase extraction (SPE). Metabolite identification will be performed using a QTrap 4000 linear ion trap mass spectrometer (ABSciex, Canada) by multi-reaction monitoring (MRM) optimized for the detection of pure standards. Metabolites will be confirmed on the basis of retention time and parent-daughter ion fragmentation transitions.

    Time frame: 12 months

  2. Genes involved in flavonoid metabolism

    Candidate genes encoding proteins involved in the flavonoid metabolism pathway will be identified from the literature and available pathway databases such as gene ontology, gene network, KEGG. Putative functional SNPs within these genes will be identified from the literature and/or online tools such genepipe and polyphen. In addition tag SNPs will be identified across the selected genes. This approach will involve the genotyping of approximately 200 single nucleotide polymorphisms (SNPs). Genotyping of these SNPs will be performed with the MassARRAY and iPlex systems of the Sequenom genotyping platform (Sequenom, San Diego, CA), which uses the MALDITOF primer extension assay. The associations of these SNPs and flavonoid metabolism will them be investigated.

    Time frame: 12 months

Secondary outcomes

  1. Effect of gut microbiota on flavonoid metabolism

    We will determine the effects of gut-microbiota variation on flavonoid metabolism. To do this, we will collect faecal samples and determine gut-microflora using faecal bacterial phylogenetic analysis using PCR to amplify 16S rDNA genes.

    Time frame: 18 months

07

Study locations

1 of 1 sites recruiting
  • Department of Nutrition, University of East Anglia
    Norwich, Norfolk NR4 7TJ, United Kingdom
    • Ingrid Matthews · Contact · i.matthews@uea.ac.uk · +44-1603593746
    • Anne-Marie Minihane, PhD · Principal investigator
    Recruiting
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 14, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01922869
Lead sponsor
University of East Anglia
Collaborators
Fred Hutchinson Cancer Center, University of Washington
Responsible party
Sponsor
First posted
Aug 14, 2013
Start date
Jul 2013
Primary completion
May 2014 (estimated)
Completion
Sep 2014 (estimated)
Last update
Aug 14, 2013

Study contacts

Sumanto Haldar, PhD
Contact
S.Haldar@uea.ac.uk
+44-1603591949
Anne-Marie Minihane, PhD
Contact
A.Minihane@uea.ac.uk
+44-1603592389
Anne-Marie Minihane, PhD
principal investigator · Department of Nutrition, University of East Anglia, Norwich, U.K.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Aug 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion